Literature DB >> 27856150

Comparison of auto-fluorescence and tetracycline fluorescence for guided bone surgery of medication-related osteonecrosis of the jaw: a randomized controlled feasibility study.

O Ristow1, S Otto2, C Geiß3, V Kehl4, M Berger5, M Troeltzsch2, S Koerdt6, B Hohlweg-Majert7, C Freudlsperger5, C Pautke3.   

Abstract

Recent studies have indicated that bone shows auto-fluorescence under an appropriate fluorescence lamp. The aim of this preliminary study was to compare the success rates of the established tetracycline fluorescence-guided bone surgery with auto-fluorescence-guided bone surgery in the treatment of medication-related osteonecrosis of the jaw (MRONJ). Forty patients suffering from MRONJ were referred for surgical treatment and were divided randomly into two groups: auto-fluorescence (n=20) or tetracycline fluorescence (n=20) guided bone surgery. The primary endpoint was treatment success, defined as the absence of exposed bone at 8 weeks after surgery. Secondary outcomes assessed were mucosal integrity, signs of infection, pain, and loss of sensitivity; these were evaluated descriptively at 10 days, 8 weeks, 6 months, and 1 year after surgery. At 8 weeks postoperative, 18/20 patients (90%) in the auto-fluorescence group and 17/20 patients (85%) in the tetracycline fluorescence group showed mucosal integrity (P>0.05). At the last follow-up, 94% in the auto-fluorescence group and 89% in the tetracycline fluorescence group presented complete mucosal coverage with no exposed bone, infection, or pain (P>0.05). There was no significant difference between the two techniques for any of the secondary outcomes (P>0.05). The results of this preliminary study show that auto-fluorescence-guided bone surgery has comparable success rates to the established tetracycline fluorescence-guided bone surgery.
Copyright © 2016 International Association of Oral and Maxillofacial Surgeons. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  BRONJ; DRONJ; MRONJ; ONJ; VELscope; auto-fluorescence; bisphosphonate; bone; bone fluorescence; necrosis of the jaw; osteonecrosis; tetracycline; therapy

Mesh:

Substances:

Year:  2016        PMID: 27856150     DOI: 10.1016/j.ijom.2016.10.008

Source DB:  PubMed          Journal:  Int J Oral Maxillofac Surg        ISSN: 0901-5027            Impact factor:   2.789


  15 in total

Review 1.  A literature review of perioperative antibiotic administration in surgery for medication-related osteonecrosis of the jaw.

Authors:  Masaya Akashi; Junya Kusumoto; Daisuke Takeda; Takashi Shigeta; Takumi Hasegawa; Takahide Komori
Journal:  Oral Maxillofac Surg       Date:  2018-10-16

2.  Use of a generic violet light in the surgical management of medication-related osteonecrosis of the jaws: a technical note.

Authors:  Caroline Ballardin; Cecilia Luiz Pereira-Stabile; Glaykon Alex Vitti Stabile
Journal:  Oral Maxillofac Surg       Date:  2018-09-01

3.  The effect of concentrated growth factor (CGF) in the surgical treatment of medication-related osteonecrosis of the jaw (MRONJ) in osteoporosis patients: a randomized controlled study.

Authors:  Meltem Ozden Yüce; Emine Adalı; Gözde Işık
Journal:  Clin Oral Investig       Date:  2021-01-03       Impact factor: 3.573

4.  Surgical treatment of 61 consecutive patients with maxillary stage 3 medication-related osteonecrosis of the jaws using a pedicled buccal fat pad.

Authors:  Sanne Werner Moeller Andersen; Ditte Gertz Mogensen; Morten Schioedt; Thomas Kofod
Journal:  Oral Maxillofac Surg       Date:  2022-04-01

Review 5.  Interventions for managing medication-related osteonecrosis of the jaw.

Authors:  Natalie H Beth-Tasdogan; Benjamin Mayer; Heba Hussein; Oliver Zolk; Jens-Uwe Peter
Journal:  Cochrane Database Syst Rev       Date:  2022-07-12

6.  Fluorescence-guided surgery for osteoradionecrosis of the jaw: a retrospective study.

Authors:  Suad Aljohani; Riham Fliefel; Teresa Franziska Brunner; Aristeidis Chronopoulos; Nada Binmadi; Sven Otto
Journal:  J Int Med Res       Date:  2022-06       Impact factor: 1.573

7.  Three-dimensional radiologic-pathologic correlation of medication-related osteonecrosis of the jaw using 3D bone SPECT/CT imaging.

Authors:  Hidetaka Miyashita; Kaori Kameyama; Mayu Morita; Taneaki Nakagawa; Tadaki Nakahara
Journal:  Dentomaxillofac Radiol       Date:  2019-07-11       Impact factor: 2.419

8.  Fluorescent tetracycline bone labeling as an intraoperative tool to debride necrotic bone during septic hip revision: a preliminary case series.

Authors:  Ernesto Muñoz-Mahamud; Jenaro Ángel Fernández-Valencia; Andreu Combalia; Laura Morata; Álex Soriano
Journal:  J Bone Jt Infect       Date:  2021-01-27

Review 9.  Interventions for managing medication-related osteonecrosis of the jaw.

Authors:  Natalie H Beth-Tasdogan; Benjamin Mayer; Heba Hussein; Oliver Zolk
Journal:  Cochrane Database Syst Rev       Date:  2017-10-06

10.  Perspective on optical imaging for functional assessment in musculoskeletal extremity trauma surgery.

Authors:  Ida L Gitajn; Gerard P Slobogean; Eric R Henderson; Arvind G von Keudell; Mitchel B Harris; John A Scolaro; Nathan N O'Hara; Jonathan T Elliott; Brian W Pogue; Shudong Jiang
Journal:  J Biomed Opt       Date:  2020-08       Impact factor: 3.170

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.